

**Area Drugs and Therapeutics Committee Meeting Minutes**

Wednesday 20<sup>th</sup> December 2023 10-12:30

Microsoft Teams Meeting

<b>Present:</b>	Mehrdad Malekian (Chair) Victoria Gemmell (Minutes) Christine Gilmour Gail Richardson Tyra Smyth Emma Harris Colin Angus (from item 4f)	Penny Brankin Linda Johnstone Kirsty Macfarlane Alistair Brown Colin Angus Christine Carswell (until item 12) Stephanie Dundas
-----------------	--	--

<b>1. Apologies:</b>	Mark Kirk David Semple
----------------------	---------------------------

<b>2. Declaration of Interest</b>	Nil
-----------------------------------	-----

Item	Notes	Action
<b>3</b>	<b><u>Minutes/Actions from the last meeting</u></b> The minutes were accepted as true records and can now be published	
<b>4</b>	<b><u>Matters Arising</u></b>	
<b>a)</b>	Ogluo-update awaited	
<b>b)</b>	IV Fluids-update awaited Expected Jan/Feb	
<b>c)</b>	Deprescribing Guideline-update This was accepted	
<b>d)</b>	NHSL HF Guideline-update awaited	
<b>e)</b>	Massive PE Guidance-update This was accepted pending some small changes Add % on pg. 3 Appendix 2-spelling of complementary It would also be helpful refer to ongoing treatment and link to general guidance of pulmonary embolism  To be shared via the RDS website	
<b>f)</b>	Orbital Cellulitis Guideline NHSL-update awaited	

5	<p><b>SMC Advice-CONFIDENTIAL</b></p> <p><b>Full Submissions</b></p> <ul style="list-style-type: none"> <li>• belantamab mafodotin (Blenrep) GlaxoSmithKline SMC2597 <b>Not Recommended FOR NOTING</b></li> <li>• pembrolizumab (Keytruda®) Merck Sharp &amp; Dohme (UK) Limited SMC2589 <b>Accepted with PAS Await advice from WoSCAN</b></li> </ul> <p><b>Ultra Orphan Reassessment</b></p> <ul style="list-style-type: none"> <li>• burosumab (Crysvita) Kyowa Kirin Ltd SMC2588 <b>Accepted with PAS FOR NOTING</b></li> </ul> <p><b>Non Submissions</b></p> <ul style="list-style-type: none"> <li>• axicabtagene ciloleucel (Yescarta®) Gilead Sciences Ltd SMC2646</li> <li>• setmelanotide (Imcivree®) Rhythm Pharmaceutical UK Ltd SMC2647</li> </ul> <p><b>FOR NOTING</b></p> <p><b>Amended Advice</b></p> <p><u>trastuzumab deruxtecan (Enhertu) Daiichi Sankyo UK Ltd SMC2608</u> <b>FOR NOTING</b></p> <p><u>deucravacitinib film-coated tablets (Sotyktu®) Bristol Myers Squibb SMC2581</u> <b>FOR NOTING</b></p> <p><u>nivolumab (Opdivo) Bristol Myers Squibb Pharmaceuticals Ltd SMC2619</u> <b>FOR NOTING</b></p> <p>VG TO CHECK DATABASE AND SEE WHAT THE STATUS IS</p> <p><b>Paediatric Licence Extensions</b></p> <p>FOR NOTING</p>	
6.	<p><b>SMC follow up CONFIDENTIAL</b></p> <ul style="list-style-type: none"> <li>• KM gave an update. Migraine services for NHSL patients are provided via GGC. They are currently updating their guidance, which will include recently SMC-approved medicines. The updated GGC guidance will be brought to ADTC for discussion in due course.</li> <li>• Empagliflozin/Dapagliflozin-HF protocol in progress</li> <li>• Icosapent-The committee agreed that as there have been no expressions of interest, this item can be designated as <i>“Not routinely available as there is a local preference for alternative medicines”</i></li> </ul>	VG
7.	<p><b>Lanarkshire Formulary</b></p> <p>The proposed change was agreed</p>	VG
8.	<p><b>Clinical Protocols</b></p> <p><b>(a)</b> Risankizumab-Crohns Disease This was approved with no changes. It was suggested that current guidance could be updated in due course to show where this medicine would sit in the current treatment pathway</p> <p><b>(b)</b> Tofadacitinib-Ankylosing spondylitis/ Upadacitinib-Ankylosing spondylitis This was approved with no changes. It was suggested that current guidance could be updated in due course to show where these medicines would sit in the pathway</p>	

	<p>(c) Paracetamol to Prevent or Treat Fever post MenB Vaccination Updated version to be discussed in January</p> <p>(d) Hypokalaemia-Paediatrics This was discussed and comments include Some duplication of text and tables. The repeated sections can be removed Flowchart-pg 7 middle bottom box-error in strength-should be 20mmols And also unable to read colour of the text in this box once printed. Add UWH after ward 19 20</p> <p>(e) Palliative Care Prescribing Record LJ updated the group with proposed changes. The changes were made a result of feedback from users. Doses have been amended to concur with Scottish Palliative Care Guidelines. JIC quantities will remain at 5 ampoules LJ will feedback comments and return for final approval</p>	
7.	<p><b><u>ADTC New Medicines Decisions</u></b> Noted and accepted</p>	
8.	<p><b><u>Unlicensed Medicines</u></b> NIL</p>	
9.	<p><b><u>Medication and Clinical risk in Lanarkshire</u></b> <a href="https://www.gov.uk/drug-safety-update">https://www.gov.uk/drug-safety-update</a> NIL</p>	
10.	<p><b><u>Regional Cancer Advisory Network</u></b> Carried over to January meeting</p>	
11.	<p><b><u>Patient Safety Alerts</u></b></p> <p>a) <b>National Patient Safety Alert-Sodium Valproate</b> VG gave an update. Plans are already in place to take forward the actions in the Alert</p> <p>b) <b>National Patient Safety Alert-Potential for inappropriate dosing of insulin when switching insulin degludec (Tresiba®) products</b> This has been shared with both primary and secondary care.</p>	
12.	<p><b><u>Lay member related items</u></b> CA informed the group of a talk given by Dr Rainey at the SHSC Forum about medicines wastage and how patients can help support cost efficiencies</p>	
13.	<p><b><u>Correspondence</u></b> NIL</p> <p>(a) <b><u>ADTC Collaborative</u></b> VG gave an update</p>	

14.	<b>Pharmacy &amp; NMAHP Prescribing Governance</b> <b>NIL</b>	
15.	<p><b><u>AOCB</u></b></p> <p>a) GR raised the issue of a National shortage of Sando K-supply not expected until February 2024 Orders have been placed for Kay-Cee-L however this contains high levels of sugar, which is not ideal for diabetic patients.</p> <p>b) A point was raised relating to guidance on Meningococcal prophylaxis. The group agreed that it would be helpful to move the current guidance to the RDS platform, under the antimicrobial section of the Guidelines page. KM will take this forward with the antimicrobial team. All 3 ED's will also hold supplies of chemoprophylaxis going forward. A group is meeting to review current communication processes to ensure all relevant parties are notified within an appropriate timescale.</p>	KM
16.	<p><b><u>Date of next meeting</u></b></p> <p>Wednesday 17<sup>TH</sup> January 2024 10am-12.30pm MS TEAMS</p>	